These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 19437245)
1. Bone marrow recovery following use of systemic (153)Sm-lexidronam and (89)Sr-chloride for bone pain palliation after myelosuppressive therapy. Papatheofanis FJ; Najib MM Int J Radiat Biol; 2009 May; 85(5):448-53. PubMed ID: 19437245 [TBL] [Abstract][Full Text] [Related]
2. Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases. Paravati AJ; Russo AL; Aitken C Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):506-10. PubMed ID: 20888141 [TBL] [Abstract][Full Text] [Related]
3. Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy. Heron DE; Brufsky A; Beriwal S; Kurman M Ann Oncol; 2008 Sep; 19(9):1639-43. PubMed ID: 18467311 [TBL] [Abstract][Full Text] [Related]
4. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study. Montesano T; Giacomobono S; Acqualagna G; Colandrea M; Di Nicola A; Travascio L; Giancamerla M; D'Apollo R; Toteda M; Ugolini F; Filesi M; Ronga G Clin Ter; 2009; 160(3):193-9. PubMed ID: 19756320 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Sartor O; Reid RH; Bushnell DL; Quick DP; Ell PJ Cancer; 2007 Feb; 109(3):637-43. PubMed ID: 17167764 [TBL] [Abstract][Full Text] [Related]
6. Strontium 89 therapy for the palliation of pain due to osseous metastases. Robinson RG; Preston DF; Schiefelbein M; Baxter KG JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352 [TBL] [Abstract][Full Text] [Related]
7. Improvement in sensory pain rating after palliative systemic radionuclide therapy in patients with advanced prostate cancer. Papatheofanis FJ; Smith C; Najib M Am J Ther; 2009; 16(2):127-32. PubMed ID: 19300039 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. Tu SM; Mathew P; Wong FC; Jones D; Johnson MM; Logothetis CJ J Clin Oncol; 2009 Jul; 27(20):3319-24. PubMed ID: 19414670 [TBL] [Abstract][Full Text] [Related]
10. Samarium Sm 153 lexidronam for the palliative treatment of dogs with primary bone tumors: 35 cases (1999-2005). Barnard SM; Zuber RM; Moore AS J Am Vet Med Assoc; 2007 Jun; 230(12):1877-81. PubMed ID: 17571994 [TBL] [Abstract][Full Text] [Related]
11. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Tripathi M; Singhal T; Chandrasekhar N; Kumar P; Bal C; Jhulka PK; Bandopadhyaya G; Malhotra A Indian J Cancer; 2006; 43(2):86-92. PubMed ID: 16790946 [TBL] [Abstract][Full Text] [Related]
12. Incident pain and analgesic consumption decrease after samarium infusion: a pilot study. Ripamonti C; Fagnoni E; Campa T; Seregni E; Maccauro M; Bombardieri E Support Care Cancer; 2007 Mar; 15(3):339-42. PubMed ID: 16967302 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120 [TBL] [Abstract][Full Text] [Related]
14. (170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation. Das T; Chakraborty S; Sarma HD; Tandon P; Banerjee S; Venkatesh M; Pillai MR Nucl Med Biol; 2009 Jul; 36(5):561-8. PubMed ID: 19520297 [TBL] [Abstract][Full Text] [Related]
15. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. Serafini AN; Houston SJ; Resche I; Quick DP; Grund FM; Ell PJ; Bertrand A; Ahmann FR; Orihuela E; Reid RH; Lerski RA; Collier BD; McKillop JH; Purnell GL; Pecking AP; Thomas FD; Harrison KA J Clin Oncol; 1998 Apr; 16(4):1574-81. PubMed ID: 9552068 [TBL] [Abstract][Full Text] [Related]
16. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Anderson P; Nuñez R Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Menda Y; Bushnell DL; Williams RD; Miller S; Thomas MO Clin Nucl Med; 2000 Sep; 25(9):698-700. PubMed ID: 10983757 [TBL] [Abstract][Full Text] [Related]
18. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. Lee CK; Aeppli DM; Unger J; Boudreau RJ; Levitt SH Am J Clin Oncol; 1996 Apr; 19(2):102-7. PubMed ID: 8610630 [TBL] [Abstract][Full Text] [Related]
19. [Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate]. Lovera C; Massardo T; Galleguillos MC; González P; Comparini B; Yáñez M; Fodor M; Gil MC; Araya G; Tomicic M Rev Med Chil; 1998 Aug; 126(8):963-71. PubMed ID: 9830748 [TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer. Dolezal J; Vizda J; Odrazka K Urol Int; 2007; 78(1):50-7. PubMed ID: 17192733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]